Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study Evaluating the Addition of Elacestrant, an Oral Selective Estrogen Receptor Degrader (SERD), to Standard-of-care Olaparib in Patients With Hormone Receptor (HR)-Positive, HER2-negative Locally Advanced or Metastatic Breast Cancer With gBRCA1/2 Mutations

NCT06201234 is registered in ClinicalTrials.gov with GBG Forschungs GmbH as lead sponsor.

NCT NCT06201234
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06201234 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study Evaluating the Addition of Elacestrant, an Oral Selective Estrogen Receptor Degrader (SERD), to Standard-of-care Olaparib in Patients With Hormone Receptor (HR)-Positive, HER2-negative Locally Advanced or Metastatic Breast Cancer With gBRCA1/2 Mutations
Lead sponsor
GBG Forschungs GmbH
Phase
Phase 2
Overall status
Recruiting
Start date
December 13, 2024
Completion date
December 31, 2028
Enrollment
176 (estimated)
Sites
36

Conditions

As the registry lists them; a condition with its own page is linked.

advanced or metastatic breast cancer, brca1 mutation, brca2 mutation, hormone receptor positive her-2 negative breast cancer